All In MedTech

FDA Clearance Tracker · P170019-S030

FoundationOne CDx (F1CDx)

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Jan 19, 2022 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Jan 19, 2022

Approved

Time to decision

202 days

Received Jul 1, 2021. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track

Device class

Class III

The decision

FDA number
P170019-S030
Device name
FoundationOne CDx (F1CDx)
Applicant location
Boston, MA
Received
Jul 1, 2021
Decided
Jan 19, 2022
Decision
Approved
Supplement type
Normal 180 Day Track
Reason for supplement
Labeling Change - Indications/instructions/shelf life/tradename
Original approval
P170019

Device type

Device class
Class III

Every decision under product code PQP

FDA's approval statement

As written in FDA's record.

Approval to expand the intended use of FoundationOne CDx (F1CDx) to expand the intended use of FoundationOne CDx (F1CDx) to include a companion diagnostic indication for identifying patients with BRAF V600 mutation-positive unresectable or metastatic melanoma, who may benefit from treatment with atezolizumab (Tecentriq) in combination with cobimetinib and vemurafenib.

Source documents

Other decisions for Foundation Medicine, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.